Why Is Quantum BioPharma In The News Today? Here’s An Important Update On Its Multiple Sclerosis Investigational Drug
Synopsis
The company intends to study the oral formulation of Lucid-MS in a mid-stage clinical trial and test its efficacy on humans as a possible treatment for people to regain mobility lost with multiple sclerosis (MS).
Quantum BioPharma (QNTM) on Monday announced that it has signed an agreement with a leading contract development and manufacturing organization to manufacture an oral drug formulation of Lucid-MS.
The agreement was signed through Quantum’s subsidiary, Huge Biopharma Australia Pty. The company intends to study the oral formulation of Lucid-MS in a mid-stage clinical trial and test its efficacy on humans as a possible treatment for people to regain mobility lost with multiple sclerosis (MS). Multiple Sclerosis is a chronic, often disabling disease that affects the brain and spinal cord.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.